CAMK2G(CAMK2g)
Sign in to save this workspaceUniProt Q13555 · PDB · AlphaFold · Substrate: ZIPtide + Ca-CaM* · Clone: C-terminal truncation
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 92.7% | 7.3% | 82.96 | 0.513 |
| 2 | Abemaciclib | 82.0% | 17.9% | 91.48 | 0.563 |
| 3 | Alectinib | 58.6% | 41.4% | 95.49 | 0.651 |
| 4 | Sunitinib | 49.0% | 51.0% | 91.73 | 0.524 |
| 5 | Midostaurin | 33.2% | 66.8% | 78.64 | 0.500 |
| 6 | Crizotinib | 32.8% | 67.2% | 91.39 | 0.581 |
| 7 | Ruxolitinib | 28.8% | 71.2% | 98.25 | 0.592 |
| 8 | Rabusertib | 22.9% | 77.1% | 98.74 | 0.687 |
| 9 | Pacritinib | 20.4% | 79.6% | 88.64 | 0.452 |
| 10 | Dabrafenib | 19.3% | 80.7% | 94.74 | 0.633 |
| 11 | Ponatinib | 18.9% | 81.1% | 78.23 | 0.534 |
| 12 | Repotrectinib | 17.2% | 82.8% | 84.21 | 0.608 |
| 13 | Encorafenib | 16.3% | 83.7% | 98.50 | 0.755 |
| 14 | Tofacitinib | 16.2% | 83.8% | 99.25 | 0.684 |
| 15 | Ibrutinib | 15.3% | 84.7% | 94.74 | 0.723 |
| 16 | Baricitinib | 14.8% | 85.2% | 97.99 | 0.616 |
| 17 | Infigratinib | 12.8% | 87.2% | 98.24 | 0.710 |
| 18 | Pazopanib | 12.4% | 87.6% | 97.49 | 0.672 |
| 19 | Capmatinib | 11.7% | 88.3% | 99.75 | 0.582 |
| 20 | Leniolisib | 11.4% | 88.6% | 100.00 | 0.604 |
Paralog block
CAMK2A, CAMK2B, CAMK2D, CAMK2G
EMT expression
- Mesenchymal log2(TPM+1): 4.32
- Epithelial log2(TPM+1): 4.51
- Fold change: -0.19
- Status: No significant change
Selectivity landscape vs inhibition on CAMK2G
Each point is one of the 92 approved drugs; color = inhibition % on CAMK2G.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…